no image available Dickens & Co. "Finding a Ray of Hope in GIST: Can Masitinib be the Breakthrough Against Advanced GIST?" "A randomized controlled trial explores the potential of masitinib as a second-line treatment for patients with advanced gastrointestinal stromal tumors that have failed imatinib therapy" Price: 27.00€